Independent medical education
The medical education activities below are non-promotional, evidenced-based, fair-balanced and can be accredited or non-accredited. The activities are developed independently by third-party providers through an educational grant from Janssen to enhance the knowledge, skills, and performance of healthcare professionals, patients, and communities.
Bladder cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Bladder Cancer: Treatment Updates Part I of Living with Bladder Cancer (Patient Education) (12/24)
- Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies
- For Caregivers: Practical Tips to Cope with Loved One’s Bladder Cancer Part II of Living with Bladder Cancer (Patient Education) (12/24)
- Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum
- Oncology Today with Dr Neil Love: Special Edition — Management of Urothelial Bladder Cancer
- Opportunities for Improved Outcomes: The Role of Targeted Therapies in Metastatic Urothelial Carcinoma (12/24)
- NCCN Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care New Approaches to Treatment of Bladder Cancer (12/24)
- Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes (12/24)
Prostate cancer
- Advancing The Latest Evidence in mCRPC Treatment Across VA Clinical Care Teams: A Regional Grand Rounds Series (12/24)
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- An Asembia Satellite Symposium: Innovations in Prostate Cancer: Unveiling Novel Therapies and the Role of the Specialty Pharmacist
- AUA2024 Prostate Cancer Courses and On-Demand Activities
- Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer
- Elevating Optimal Care for Prostate Cancer: Applying Personalized Treatment Options to Improve Outcomes
- Evolving Paradigm of PARP Inhibitors and Combination Therapies for mCRPC
- Expert Context from AUA 2024: Revolutionizing Prostate Cancer Treatment
- “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
- Improving the Overall Safety and Quality of Care for Your Patients with Metastatic Hormone-Sensitive Prostate Cancer: How Does Your Approach Compare with the Experts?
- Medscape Onsite: Prostate and Bladder Cancer Updates
- Navigating Therapeutic Choices in Prostate Cancer: Effective Decision-Making for Patient-Centric Care (12/24)
- Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer
- Treatment Advances for Advanced Prostate Cancer: Guideline Updates and Newer Therapies (12/24)
- The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion
- (2024 PUPC) Evidence-Based Strategies to Optimize Prostate Cancer Screening and Outcomes
Non-small cell lung cancer
- AMCP: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology
- Biomarker Testing: Shaping Personalized Medicine (Episode 2)
- Can Molecular Testing Identify Which mNSCLC Patients Will Benefit From New Targeted Tx?
- Clinical Trials: How They Transform the Treatment of Cancer
- From Screening to Survivor Support: The Role of Primary Care Providers in the Management of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (12/24)
- Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
- Highlights from Madrid on Targeted Therapy for Advanced NSCLC
- Interprofessional Approaches to Managing Adverse Events in EGFR-Mutated NSCLC
- Leading Developments and Current Questions in Lung Cancer Panel Discussions (Patient Education) (12/24)
- Navigating Rapid Sea Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC
- New Horizons in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Considerations on the Role of EGFR Exon 20-Targeted Therapies
- Novel Therapeutics: Changing the Treatment Landscape for NSCLC (Episode 3)
- Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy (Episode 4)
- Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Lung Cancer with EGFR Mutations
- The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC (Episode 1)
- Updates and Evidence-Based Strategies in Non-Small Cell Lung Cancer: A Focus on Molecular Testing, Targeted Treatment, and Adverse Event Management (12/24)
- 2024 Great Debates & Updates in Lung Cancers: Targeted Strategies in the Management of Non-Small Cell Lung Cancer: A Focus on EFGR Gene Mutations
Lymphoma
- Highlights From Bruton’s Tyrosine Kinase Inhibitors: Updates and Advancements in the Treatment and Management of CLL/SLL
- New Pathways in the Treatment of Mantle Cell Lymphoma
- What I Tell My Patients: New Treatments and Clinical Trials —Chronic Lymphocytic Leukemia
Multiple myeloma
- Current and Emerging Treatment Strategies in Multiple Myeloma: Managed Care Considerations for Improved Patient Outcomes
- Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
- Demystifying the Details of T-Cell-Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
- Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
- Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
- Management of CRS and ICANS with CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma: 2023 ASH Annual Meeting Highlights from San Diego
- Overcoming Barriers to Care in Multiple Myeloma: Recognizing the Problem and Focusing on Solutions
- Oncology Morning Commute: Emerging Data on BTCE in RRMM
- Oncology Morning Commute: Tying a T-cell to the Tumor Cell in RRMM
- Oncology Morning Commute: Using Bispecifics for the Treatment of Multiple Myeloma in Clinical Practice
- Recent Advances in BCMA-Directed Treatment in Multiple Myeloma – Insights and Application for Managed Care
- Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations
- The Heterogeneity, Therapeutic Advancements, and Updated Guidelines for the Treatment of RRMM
- The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms